Navigation Links
Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Date:11/28/2007

Company Plans to Initiate Phase III Program in First Half of 2008

LEXINGTON, Mass., Nov. 28 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced positive results from its Phase II octreotide implant trial in patients with acromegaly, a disorder characterized by excessive blood levels of growth hormone (GH) and insulin- like growth factor 1 (IGF-1). The implant utilizes the Company's patented Hydron technology to deliver effective levels of octreotide for six months. Octreotide is a synthetic peptide that mimics the natural hormone somatostatin to block release of GH. In the recently completed six-month trial, the octreotide implant effectively suppressed levels of GH and IGF-1 at rates similar to those seen with current FDA approved injectable formulations of octreotide. In addition, the drug was well tolerated.

"I am extremely pleased to report the successful completion of our octreotide implant trial and we are looking forward to the initiation of our Phase III program in the first half of 2008," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The market opportunity for a six-month octreotide implant for the treatment of acromegaly is substantial. The results of the trial demonstrate the potential of our octreotide implant, the only once every six month treatment, to improve the treatment options for people who suffer from this life-long debilitating condition. In addition, based on the successful results of this trial, we are exploring opportunities to expand our octreotide development program to address other indications where injectable formulations of octreotide are currently utilized, including carcinoid tumors."

The trial w
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- Market ... Hydrochloride Industry, 2009-2019 is a professional and ... Oxybutynin Hydrochloride industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Oxybutynin Hydrochloride listing their product ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
(Date:9/19/2014)... September 19, 2014 According ... Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise ... Advanced technologies - Global Forecast to 2019" published ... to reach $19,786.3 Million by 2019 from $14,240.0 ... from 2014 to 2019. Browse 74 ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
(Date:9/20/2014)... (PRWEB) September 20, 2014 The first ... is now in its third week in the U.S. ... LLC reports. Court documents indicate that the week opened ... with testimony from a DePuy Orthopaedics vice president, who ... of the company’s Pinnacle hip replacement. According to Reuters, ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
(Date:9/19/2014)... 20, 2014 Nearly 780 Risperdal lawsuits ... Pleas where a meeting took place to discuss the ... in the court’s mass tort program. Attorneys for ... past week at the Complex Litigation Center in Philadelphia’s ... pretrial proceedings. The Risperdal lawsuits filed against Johnson & ...
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
Breaking Medicine News(10 mins):Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... (BRONX, NY) The National Institute of Diabetes and ... of Health (NIH) has awarded Albert Einstein College of ... for the continuation of its Diabetes Research and Training ... supplemental grant for equipment and additional pilot and feasibility ...
... and a friend dares you to eat a raw crayfish ... a severe parasitic infection. Physicians at Washington University School of ... six people who had consumed raw crayfish from streams and rivers ... three have been diagnosed since last September; the latest in April. ...
... high-risk women opt for lumpectomy , TUESDAY, May 25 ... before surgery enhances their chances of being able to ... new research suggests. , The observation was based on ... United States. It focused on postmenopausal women who had ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
... indicated higher, lower risk of disease, study finds , ... germs living in your gut could affect your risk ... signs of the existence of some germs "are more ... can develop into cancer, while other bacterial signatures are ...
... in French . Montreal, May 25, 2010 ... French and English, at local bookstores and pharmacies. Dr. Jean-Daniel ... Department of Ophthalmology, along with two colleagues from France, have ... Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate ...
Cached Medicine News:Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:Breast Cancer Study Offers New Hope 2Health News:Book on vision loss: AMD affects 1 million Canadians 2
... catheter is designed to remove thrombus ... saline jets travel backwards at half ... a low pressure zone causing a ... the catheter where it is fragmented ...
... Electroanatomical Mapping System combines the legendary accuracy ... ease of Windows* software. It integrates ... new tools that enhance your clinical capabilities ... into the future of EP. The ...
... are meeting the clinical needs of ... anesthesiologists. And, they are of the ... Medtronic.,Effective pacing with the adjustment of ... quick battery changes. Both the ...
... The Kantrowitz CardioVad is a unique left ventricular ... more effectively. It is being used in a ... heart failure as part of an FDA-approved Feasibility ... and disconnect the external power source for minutes ...
Medicine Products: